BLINCYTO (blinatumomab), monoclonal antibody

Moderate improvement in the treatment of Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia

• BLINCYTO has Marketing Authorisation in the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (Ph- B-ALL).
• Its efficacy in terms of complete remission (CR) and complete remission with partial haematological recovery (CRh) has been demonstrated. A little less than half of patients (40%) who achieved remission had received an allogeneic stem cell transplant.
• Clinical data are limited, pending the results of a comparative study.
• This is a second-line and subsequent treatment for Ph- B-ALL.